Oruka surges as long-acting psoriasis drug shows early promise
Summary
A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
Description
A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source